nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP2D6—Niacin—atherosclerosis	0.106	0.3	CbGbCtD
Dexmedetomidine—CYP2D6—Simvastatin—atherosclerosis	0.0841	0.237	CbGbCtD
Dexmedetomidine—CYP2D6—Lovastatin—atherosclerosis	0.0823	0.232	CbGbCtD
Dexmedetomidine—CYP2D6—Pravastatin—atherosclerosis	0.0823	0.232	CbGbCtD
Dexmedetomidine—Nephropathy—Rosuvastatin—atherosclerosis	0.0116	0.0334	CcSEcCtD
Dexmedetomidine—Pregnancy—Lovastatin—atherosclerosis	0.00821	0.0237	CcSEcCtD
Dexmedetomidine—Pregnancy—Simvastatin—atherosclerosis	0.00768	0.0222	CcSEcCtD
Dexmedetomidine—Generalised oedema—Niacin—atherosclerosis	0.00673	0.0194	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.00556	0.0161	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.00479	0.0138	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Lovastatin—atherosclerosis	0.00466	0.0135	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Ezetimibe—atherosclerosis	0.00457	0.0132	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Niacin—atherosclerosis	0.0044	0.0127	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Simvastatin—atherosclerosis	0.00436	0.0126	CcSEcCtD
Dexmedetomidine—Renal failure acute—Rosuvastatin—atherosclerosis	0.00432	0.0125	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Pravastatin—atherosclerosis	0.00394	0.0114	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Lovastatin—atherosclerosis	0.00389	0.0112	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Lovastatin—atherosclerosis	0.00387	0.0112	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Ezetimibe—atherosclerosis	0.00382	0.011	CcSEcCtD
Dexmedetomidine—Fluid retention—Niacin—atherosclerosis	0.0038	0.011	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Simvastatin—atherosclerosis	0.00364	0.0105	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Simvastatin—atherosclerosis	0.00362	0.0105	CcSEcCtD
Dexmedetomidine—Abnormal vision—Niacin—atherosclerosis	0.00349	0.0101	CcSEcCtD
Dexmedetomidine—Atrial fibrillation—Simvastatin—atherosclerosis	0.00334	0.00965	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Niacin—atherosclerosis	0.00333	0.00961	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Pravastatin—atherosclerosis	0.00329	0.00951	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Pravastatin—atherosclerosis	0.00327	0.00946	CcSEcCtD
Dexmedetomidine—Renal failure acute—Pravastatin—atherosclerosis	0.0031	0.00896	CcSEcCtD
Dexmedetomidine—Atrial fibrillation—Niacin—atherosclerosis	0.00307	0.00886	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.00302	0.00872	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00299	0.00864	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.00299	0.00864	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00293	0.00846	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00256	0.00739	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Lovastatin—atherosclerosis	0.00253	0.00732	CcSEcCtD
Dexmedetomidine—Abdominal distension—Niacin—atherosclerosis	0.00253	0.00731	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00252	0.00729	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00251	0.00724	CcSEcCtD
Dexmedetomidine—Abdominal distension—Pravastatin—atherosclerosis	0.00249	0.00719	CcSEcCtD
Dexmedetomidine—Arrhythmia—Rosuvastatin—atherosclerosis	0.00247	0.00713	CcSEcCtD
Dexmedetomidine—Mental disorder—Rosuvastatin—atherosclerosis	0.00242	0.00699	CcSEcCtD
Dexmedetomidine—Sweating increased—Pravastatin—atherosclerosis	0.00241	0.00696	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Simvastatin—atherosclerosis	0.00239	0.00691	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Ezetimibe—atherosclerosis	0.00226	0.00654	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00217	0.00628	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Pravastatin—atherosclerosis	0.00216	0.00625	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Pravastatin—atherosclerosis	0.00216	0.00625	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Pravastatin—atherosclerosis	0.00214	0.00619	CcSEcCtD
Dexmedetomidine—Chills—Lovastatin—atherosclerosis	0.0021	0.00607	CcSEcCtD
Dexmedetomidine—Angiopathy—Ezetimibe—atherosclerosis	0.00208	0.00602	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00207	0.00598	CcSEcCtD
Dexmedetomidine—Haemoglobin—Niacin—atherosclerosis	0.00202	0.00584	CcSEcCtD
Dexmedetomidine—Mental disorder—Ezetimibe—atherosclerosis	0.00201	0.00581	CcSEcCtD
Dexmedetomidine—Haemorrhage—Niacin—atherosclerosis	0.00201	0.00581	CcSEcCtD
Dexmedetomidine—Malnutrition—Ezetimibe—atherosclerosis	0.002	0.00578	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Niacin—atherosclerosis	0.00198	0.00572	CcSEcCtD
Dexmedetomidine—Confusional state—Rosuvastatin—atherosclerosis	0.00198	0.00572	CcSEcCtD
Dexmedetomidine—Chills—Simvastatin—atherosclerosis	0.00196	0.00568	CcSEcCtD
Dexmedetomidine—Infection—Rosuvastatin—atherosclerosis	0.00195	0.00563	CcSEcCtD
Dexmedetomidine—Visual impairment—Niacin—atherosclerosis	0.00194	0.0056	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00192	0.00555	CcSEcCtD
Dexmedetomidine—Mental disorder—Simvastatin—atherosclerosis	0.00192	0.00554	CcSEcCtD
Dexmedetomidine—Visual impairment—Pravastatin—atherosclerosis	0.00191	0.00551	CcSEcCtD
Dexmedetomidine—Anaemia—Ezetimibe—atherosclerosis	0.00185	0.00534	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Pravastatin—atherosclerosis	0.00184	0.00531	CcSEcCtD
Dexmedetomidine—Angiopathy—Niacin—atherosclerosis	0.00182	0.00527	CcSEcCtD
Dexmedetomidine—Chills—Niacin—atherosclerosis	0.0018	0.00521	CcSEcCtD
Dexmedetomidine—Arrhythmia—Niacin—atherosclerosis	0.0018	0.00519	CcSEcCtD
Dexmedetomidine—Chills—Pravastatin—atherosclerosis	0.00178	0.00513	CcSEcCtD
Dexmedetomidine—Arrhythmia—Pravastatin—atherosclerosis	0.00177	0.00511	CcSEcCtD
Dexmedetomidine—Anaemia—Simvastatin—atherosclerosis	0.00176	0.00509	CcSEcCtD
Dexmedetomidine—Malnutrition—Niacin—atherosclerosis	0.00175	0.00506	CcSEcCtD
Dexmedetomidine—Anxiety—Lovastatin—atherosclerosis	0.00173	0.005	CcSEcCtD
Dexmedetomidine—Hypertension—Ezetimibe—atherosclerosis	0.00173	0.00499	CcSEcCtD
Dexmedetomidine—Dry mouth—Lovastatin—atherosclerosis	0.0017	0.0049	CcSEcCtD
Dexmedetomidine—Pain—Rosuvastatin—atherosclerosis	0.00168	0.00485	CcSEcCtD
Dexmedetomidine—Constipation—Rosuvastatin—atherosclerosis	0.00168	0.00485	CcSEcCtD
Dexmedetomidine—Confusional state—Lovastatin—atherosclerosis	0.00168	0.00485	CcSEcCtD
Dexmedetomidine—Dry mouth—Ezetimibe—atherosclerosis	0.00166	0.00481	CcSEcCtD
Dexmedetomidine—Infection—Lovastatin—atherosclerosis	0.00165	0.00477	CcSEcCtD
Dexmedetomidine—Confusional state—Ezetimibe—atherosclerosis	0.00164	0.00475	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Lovastatin—atherosclerosis	0.00163	0.00471	CcSEcCtD
Dexmedetomidine—Infection—Ezetimibe—atherosclerosis	0.00162	0.00468	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00162	0.00467	CcSEcCtD
Dexmedetomidine—Anxiety—Simvastatin—atherosclerosis	0.00162	0.00467	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.0016	0.00464	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.0016	0.00461	CcSEcCtD
Dexmedetomidine—Anaemia—Pravastatin—atherosclerosis	0.00159	0.0046	CcSEcCtD
Dexmedetomidine—Confusional state—Simvastatin—atherosclerosis	0.00157	0.00453	CcSEcCtD
Dexmedetomidine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00155	0.00448	CcSEcCtD
Dexmedetomidine—Infection—Simvastatin—atherosclerosis	0.00155	0.00447	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Simvastatin—atherosclerosis	0.00152	0.0044	CcSEcCtD
Dexmedetomidine—Hypertension—Pravastatin—atherosclerosis	0.00149	0.0043	CcSEcCtD
Dexmedetomidine—Dyspnoea—Lovastatin—atherosclerosis	0.00148	0.00428	CcSEcCtD
Dexmedetomidine—Anxiety—Pravastatin—atherosclerosis	0.00146	0.00422	CcSEcCtD
Dexmedetomidine—Dry mouth—Niacin—atherosclerosis	0.00146	0.00421	CcSEcCtD
Dexmedetomidine—Dyspnoea—Ezetimibe—atherosclerosis	0.00145	0.0042	CcSEcCtD
Dexmedetomidine—Pain—Lovastatin—atherosclerosis	0.00142	0.00411	CcSEcCtD
Dexmedetomidine—Constipation—Lovastatin—atherosclerosis	0.00142	0.00411	CcSEcCtD
Dexmedetomidine—Confusional state—Pravastatin—atherosclerosis	0.00142	0.0041	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00141	0.00407	CcSEcCtD
Dexmedetomidine—Infection—Pravastatin—atherosclerosis	0.0014	0.00404	CcSEcCtD
Dexmedetomidine—Pain—Ezetimibe—atherosclerosis	0.00139	0.00403	CcSEcCtD
Dexmedetomidine—Constipation—Ezetimibe—atherosclerosis	0.00139	0.00403	CcSEcCtD
Dexmedetomidine—Tachycardia—Niacin—atherosclerosis	0.00139	0.00403	CcSEcCtD
Dexmedetomidine—Dyspnoea—Simvastatin—atherosclerosis	0.00139	0.00401	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Niacin—atherosclerosis	0.00138	0.00399	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Pravastatin—atherosclerosis	0.00138	0.00398	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Lovastatin—atherosclerosis	0.00137	0.00396	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00136	0.00393	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Pravastatin—atherosclerosis	0.00136	0.00393	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00134	0.00388	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00134	0.00388	CcSEcCtD
Dexmedetomidine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00134	0.00388	CcSEcCtD
Dexmedetomidine—Hypotension—Niacin—atherosclerosis	0.00133	0.00386	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00133	0.00385	CcSEcCtD
Dexmedetomidine—Constipation—Simvastatin—atherosclerosis	0.00133	0.00384	CcSEcCtD
Dexmedetomidine—Pain—Simvastatin—atherosclerosis	0.00133	0.00384	CcSEcCtD
Dexmedetomidine—Abdominal pain—Lovastatin—atherosclerosis	0.00131	0.0038	CcSEcCtD
Dexmedetomidine—Body temperature increased—Lovastatin—atherosclerosis	0.00131	0.0038	CcSEcCtD
Dexmedetomidine—Dizziness—Rosuvastatin—atherosclerosis	0.0013	0.00375	CcSEcCtD
Dexmedetomidine—Abdominal pain—Ezetimibe—atherosclerosis	0.00129	0.00373	CcSEcCtD
Dexmedetomidine—Body temperature increased—Ezetimibe—atherosclerosis	0.00129	0.00373	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Simvastatin—atherosclerosis	0.00128	0.0037	CcSEcCtD
Dexmedetomidine—Dyspnoea—Niacin—atherosclerosis	0.00127	0.00368	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00127	0.00368	CcSEcCtD
Dexmedetomidine—Somnolence—Niacin—atherosclerosis	0.00127	0.00367	CcSEcCtD
Dexmedetomidine—Dyspnoea—Pravastatin—atherosclerosis	0.00125	0.00362	CcSEcCtD
Dexmedetomidine—Rash—Rosuvastatin—atherosclerosis	0.00124	0.00358	CcSEcCtD
Dexmedetomidine—Dermatitis—Rosuvastatin—atherosclerosis	0.00124	0.00357	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Niacin—atherosclerosis	0.00123	0.00356	CcSEcCtD
Dexmedetomidine—Body temperature increased—Simvastatin—atherosclerosis	0.00123	0.00355	CcSEcCtD
Dexmedetomidine—Abdominal pain—Simvastatin—atherosclerosis	0.00123	0.00355	CcSEcCtD
Dexmedetomidine—Headache—Rosuvastatin—atherosclerosis	0.00123	0.00355	CcSEcCtD
Dexmedetomidine—Pain—Niacin—atherosclerosis	0.00122	0.00353	CcSEcCtD
Dexmedetomidine—Constipation—Pravastatin—atherosclerosis	0.0012	0.00348	CcSEcCtD
Dexmedetomidine—Pain—Pravastatin—atherosclerosis	0.0012	0.00348	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Niacin—atherosclerosis	0.00117	0.00337	CcSEcCtD
Dexmedetomidine—Nausea—Rosuvastatin—atherosclerosis	0.00117	0.00337	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Pravastatin—atherosclerosis	0.00116	0.00335	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00115	0.00332	CcSEcCtD
Dexmedetomidine—Diarrhoea—Lovastatin—atherosclerosis	0.00114	0.00329	CcSEcCtD
Dexmedetomidine—Body temperature increased—Niacin—atherosclerosis	0.00113	0.00326	CcSEcCtD
Dexmedetomidine—Abdominal pain—Niacin—atherosclerosis	0.00113	0.00326	CcSEcCtD
Dexmedetomidine—Diarrhoea—Ezetimibe—atherosclerosis	0.00112	0.00322	CcSEcCtD
Dexmedetomidine—Abdominal pain—Pravastatin—atherosclerosis	0.00111	0.00321	CcSEcCtD
Dexmedetomidine—Body temperature increased—Pravastatin—atherosclerosis	0.00111	0.00321	CcSEcCtD
Dexmedetomidine—Dizziness—Lovastatin—atherosclerosis	0.0011	0.00318	CcSEcCtD
Dexmedetomidine—Dizziness—Ezetimibe—atherosclerosis	0.00108	0.00312	CcSEcCtD
Dexmedetomidine—Diarrhoea—Simvastatin—atherosclerosis	0.00106	0.00308	CcSEcCtD
Dexmedetomidine—Vomiting—Lovastatin—atherosclerosis	0.00106	0.00306	CcSEcCtD
Dexmedetomidine—Rash—Lovastatin—atherosclerosis	0.00105	0.00303	CcSEcCtD
Dexmedetomidine—Dermatitis—Lovastatin—atherosclerosis	0.00105	0.00303	CcSEcCtD
Dexmedetomidine—Headache—Lovastatin—atherosclerosis	0.00104	0.00301	CcSEcCtD
Dexmedetomidine—Vomiting—Ezetimibe—atherosclerosis	0.00104	0.003	CcSEcCtD
Dexmedetomidine—Dizziness—Simvastatin—atherosclerosis	0.00103	0.00297	CcSEcCtD
Dexmedetomidine—Rash—Ezetimibe—atherosclerosis	0.00103	0.00297	CcSEcCtD
Dexmedetomidine—Dermatitis—Ezetimibe—atherosclerosis	0.00103	0.00297	CcSEcCtD
Dexmedetomidine—Headache—Ezetimibe—atherosclerosis	0.00102	0.00295	CcSEcCtD
Dexmedetomidine—Vomiting—Simvastatin—atherosclerosis	0.000989	0.00286	CcSEcCtD
Dexmedetomidine—Nausea—Lovastatin—atherosclerosis	0.000988	0.00285	CcSEcCtD
Dexmedetomidine—Rash—Simvastatin—atherosclerosis	0.000981	0.00283	CcSEcCtD
Dexmedetomidine—Dermatitis—Simvastatin—atherosclerosis	0.00098	0.00283	CcSEcCtD
Dexmedetomidine—Diarrhoea—Niacin—atherosclerosis	0.000977	0.00282	CcSEcCtD
Dexmedetomidine—Headache—Simvastatin—atherosclerosis	0.000974	0.00282	CcSEcCtD
Dexmedetomidine—Nausea—Ezetimibe—atherosclerosis	0.000969	0.0028	CcSEcCtD
Dexmedetomidine—Diarrhoea—Pravastatin—atherosclerosis	0.000962	0.00278	CcSEcCtD
Dexmedetomidine—Dizziness—Niacin—atherosclerosis	0.000944	0.00273	CcSEcCtD
Dexmedetomidine—Dizziness—Pravastatin—atherosclerosis	0.00093	0.00269	CcSEcCtD
Dexmedetomidine—Nausea—Simvastatin—atherosclerosis	0.000924	0.00267	CcSEcCtD
Dexmedetomidine—Vomiting—Niacin—atherosclerosis	0.000908	0.00262	CcSEcCtD
Dexmedetomidine—Rash—Niacin—atherosclerosis	0.000901	0.0026	CcSEcCtD
Dexmedetomidine—Dermatitis—Niacin—atherosclerosis	0.0009	0.0026	CcSEcCtD
Dexmedetomidine—Headache—Niacin—atherosclerosis	0.000895	0.00259	CcSEcCtD
Dexmedetomidine—Vomiting—Pravastatin—atherosclerosis	0.000894	0.00258	CcSEcCtD
Dexmedetomidine—Rash—Pravastatin—atherosclerosis	0.000887	0.00256	CcSEcCtD
Dexmedetomidine—Dermatitis—Pravastatin—atherosclerosis	0.000886	0.00256	CcSEcCtD
Dexmedetomidine—Headache—Pravastatin—atherosclerosis	0.000881	0.00255	CcSEcCtD
Dexmedetomidine—Nausea—Niacin—atherosclerosis	0.000848	0.00245	CcSEcCtD
Dexmedetomidine—Nausea—Pravastatin—atherosclerosis	0.000835	0.00241	CcSEcCtD
Dexmedetomidine—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	3.36e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	3.36e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTM1—atherosclerosis	3.35e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—HMGCR—atherosclerosis	3.34e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CG—atherosclerosis	3.34e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—LEP—atherosclerosis	3.31e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—APOE—atherosclerosis	3.31e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CG—atherosclerosis	3.31e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—LPL—atherosclerosis	3.29e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CAV1—atherosclerosis	3.28e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—APOA1—atherosclerosis	3.27e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NAMPT—atherosclerosis	3.26e-05	0.000109	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—APOB—atherosclerosis	3.25e-05	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	3.25e-05	0.000109	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	3.24e-05	0.000109	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—LIPC—atherosclerosis	3.24e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PDGFB—atherosclerosis	3.23e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	3.23e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MTHFR—atherosclerosis	3.23e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOC3—atherosclerosis	3.22e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PPARG—atherosclerosis	3.22e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GPX1—atherosclerosis	3.21e-05	0.000107	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—LDLR—atherosclerosis	3.2e-05	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PDGFB—atherosclerosis	3.18e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—MAPK3—atherosclerosis	3.17e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PPARA—atherosclerosis	3.16e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTM1—atherosclerosis	3.16e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ESR1—atherosclerosis	3.16e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—INS—atherosclerosis	3.16e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AGT—atherosclerosis	3.16e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—AKT1—atherosclerosis	3.14e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APOB—atherosclerosis	3.14e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—INS—atherosclerosis	3.13e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CETP—atherosclerosis	3.13e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CD36—atherosclerosis	3.13e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—F2—atherosclerosis	3.12e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	3.11e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AGT—atherosclerosis	3.11e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—LPL—atherosclerosis	3.1e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—LEP—atherosclerosis	3.09e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APOE—atherosclerosis	3.09e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	3.09e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCL2—atherosclerosis	3.08e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AGT—atherosclerosis	3.06e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	3.06e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CAV1—atherosclerosis	3.06e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APOA1—atherosclerosis	3.06e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—LEP—atherosclerosis	3.04e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APOE—atherosclerosis	3.04e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF1—atherosclerosis	3.03e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GPX1—atherosclerosis	3.03e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CAV1—atherosclerosis	3.01e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APOA1—atherosclerosis	3.01e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—APOE—atherosclerosis	3e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—LPL—atherosclerosis	3e-05	0.0001	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SCARB1—atherosclerosis	2.99e-05	0.0001	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CG—atherosclerosis	2.99e-05	0.0001	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CAV1—atherosclerosis	2.98e-05	9.96e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.97e-05	9.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—APOA1—atherosclerosis	2.97e-05	9.94e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MTHFR—atherosclerosis	2.96e-05	9.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ESR1—atherosclerosis	2.95e-05	9.88e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CD36—atherosclerosis	2.95e-05	9.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—F2—atherosclerosis	2.92e-05	9.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.92e-05	9.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	2.91e-05	9.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARA—atherosclerosis	2.91e-05	9.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ESR1—atherosclerosis	2.9e-05	9.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ALB—atherosclerosis	2.9e-05	9.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SERPINE1—atherosclerosis	2.88e-05	9.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—F2—atherosclerosis	2.87e-05	9.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—MAPK3—atherosclerosis	2.86e-05	9.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	2.84e-05	9.5e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HMGCR—atherosclerosis	2.83e-05	9.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—INS—atherosclerosis	2.83e-05	9.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	2.82e-05	9.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AGT—atherosclerosis	2.81e-05	9.42e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MTHFR—atherosclerosis	2.79e-05	9.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CG—atherosclerosis	2.79e-05	9.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCL2—atherosclerosis	2.78e-05	9.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—NOS3—atherosclerosis	2.77e-05	9.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—APOE—atherosclerosis	2.76e-05	9.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOS3—atherosclerosis	2.75e-05	9.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CG—atherosclerosis	2.75e-05	9.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARA—atherosclerosis	2.74e-05	9.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF1—atherosclerosis	2.73e-05	9.15e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CAV1—atherosclerosis	2.73e-05	9.15e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—APOA1—atherosclerosis	2.73e-05	9.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CG—atherosclerosis	2.71e-05	9.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK3—atherosclerosis	2.67e-05	8.94e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AGT—atherosclerosis	2.65e-05	8.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—INS—atherosclerosis	2.64e-05	8.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK3—atherosclerosis	2.63e-05	8.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	2.63e-05	8.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PPARG—atherosclerosis	2.62e-05	8.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—APOE—atherosclerosis	2.6e-05	8.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—INS—atherosclerosis	2.6e-05	8.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCL2—atherosclerosis	2.6e-05	8.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SERPINE1—atherosclerosis	2.6e-05	8.69e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CAV1—atherosclerosis	2.58e-05	8.62e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—APOA1—atherosclerosis	2.57e-05	8.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—INS—atherosclerosis	2.57e-05	8.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AGT—atherosclerosis	2.56e-05	8.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCL2—atherosclerosis	2.56e-05	8.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1—atherosclerosis	2.55e-05	8.55e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—HMOX1—atherosclerosis	2.55e-05	8.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—atherosclerosis	2.55e-05	8.54e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	2.55e-05	8.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—atherosclerosis	2.53e-05	8.48e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCA1—atherosclerosis	2.52e-05	8.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1—atherosclerosis	2.51e-05	8.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APOE—atherosclerosis	2.51e-05	8.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—LEP—atherosclerosis	2.51e-05	8.4e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CG—atherosclerosis	2.49e-05	8.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	2.49e-05	8.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	2.48e-05	8.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOS3—atherosclerosis	2.48e-05	8.3e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APOB—atherosclerosis	2.44e-05	8.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—atherosclerosis	2.44e-05	8.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SERPINE1—atherosclerosis	2.43e-05	8.12e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARG—atherosclerosis	2.4e-05	8.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	2.4e-05	8.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	2.39e-05	7.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—atherosclerosis	2.38e-05	7.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—F2—atherosclerosis	2.37e-05	7.93e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—INS—atherosclerosis	2.36e-05	7.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—atherosclerosis	2.35e-05	7.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—atherosclerosis	2.35e-05	7.87e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—atherosclerosis	2.35e-05	7.85e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—LPL—atherosclerosis	2.33e-05	7.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—atherosclerosis	2.32e-05	7.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	2.32e-05	7.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	2.28e-05	7.63e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GPX1—atherosclerosis	2.28e-05	7.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	2.27e-05	7.59e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARG—atherosclerosis	2.26e-05	7.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NOS3—atherosclerosis	2.25e-05	7.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—INS—atherosclerosis	2.22e-05	7.43e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CD36—atherosclerosis	2.22e-05	7.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	2.2e-05	7.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	2.2e-05	7.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	2.18e-05	7.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	2.17e-05	7.26e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HMOX1—atherosclerosis	2.16e-05	7.24e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—atherosclerosis	2.16e-05	7.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—INS—atherosclerosis	2.15e-05	7.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	2.14e-05	7.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	2.14e-05	7.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	2.12e-05	7.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	2.11e-05	7.06e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—atherosclerosis	2.1e-05	7.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	2.09e-05	7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	2.07e-05	6.95e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOB—atherosclerosis	2.07e-05	6.93e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NOS3—atherosclerosis	2.07e-05	6.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARA—atherosclerosis	2.06e-05	6.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—atherosclerosis	2.06e-05	6.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	2.05e-05	6.88e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—atherosclerosis	2.04e-05	6.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	2.02e-05	6.77e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—atherosclerosis	2.01e-05	6.74e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AGT—atherosclerosis	2e-05	6.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	1.99e-05	6.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	1.98e-05	6.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	1.98e-05	6.62e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—LPL—atherosclerosis	1.98e-05	6.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.97e-05	6.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	1.97e-05	6.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	1.96e-05	6.56e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APOE—atherosclerosis	1.96e-05	6.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	1.95e-05	6.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	1.95e-05	6.54e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NOS3—atherosclerosis	1.95e-05	6.52e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CAV1—atherosclerosis	1.94e-05	6.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	1.93e-05	6.48e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APOA1—atherosclerosis	1.93e-05	6.47e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GPX1—atherosclerosis	1.93e-05	6.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	1.93e-05	6.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	1.92e-05	6.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—atherosclerosis	1.89e-05	6.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.88e-05	6.3e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CD36—atherosclerosis	1.88e-05	6.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	1.87e-05	6.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	1.86e-05	6.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	1.84e-05	6.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	1.83e-05	6.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	1.82e-05	6.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.81e-05	6.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	1.81e-05	6.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	1.8e-05	6.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	1.79e-05	5.98e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—atherosclerosis	1.78e-05	5.96e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.78e-05	5.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.78e-05	5.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.77e-05	5.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	1.77e-05	5.92e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.77e-05	5.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARA—atherosclerosis	1.75e-05	5.85e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARG—atherosclerosis	1.7e-05	5.71e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AGT—atherosclerosis	1.69e-05	5.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	1.69e-05	5.66e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—INS—atherosclerosis	1.67e-05	5.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.67e-05	5.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	1.67e-05	5.58e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOE—atherosclerosis	1.66e-05	5.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	1.65e-05	5.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAV1—atherosclerosis	1.64e-05	5.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	1.64e-05	5.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	1.64e-05	5.49e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOA1—atherosclerosis	1.64e-05	5.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	1.63e-05	5.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.61e-05	5.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.59e-05	5.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	1.58e-05	5.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	1.55e-05	5.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—atherosclerosis	1.53e-05	5.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	1.53e-05	5.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	1.51e-05	5.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	1.51e-05	5.04e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.5e-05	5.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	1.49e-05	5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	1.47e-05	4.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NOS3—atherosclerosis	1.47e-05	4.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	1.46e-05	4.9e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARG—atherosclerosis	1.44e-05	4.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—INS—atherosclerosis	1.42e-05	4.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—atherosclerosis	1.37e-05	4.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	1.36e-05	4.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	1.34e-05	4.49e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.34e-05	4.49e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—atherosclerosis	1.3e-05	4.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.28e-05	4.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—atherosclerosis	1.27e-05	4.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	1.26e-05	4.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.24e-05	4.16e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NOS3—atherosclerosis	1.24e-05	4.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—atherosclerosis	1.24e-05	4.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.15e-05	3.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	1.14e-05	3.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.14e-05	3.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.14e-05	3.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.06e-05	3.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.05e-05	3.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—atherosclerosis	1.03e-05	3.46e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—atherosclerosis	9.5e-06	3.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	9.37e-06	3.14e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—atherosclerosis	8.95e-06	3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	8.65e-06	2.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—atherosclerosis	6.74e-06	2.26e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—atherosclerosis	5.71e-06	1.91e-05	CbGpPWpGaD
